1
|
McGuckin MB, Hutton AR, Davis ER, Sabri AH, Ripolin A, Himawan A, Naser YA, Ghanma R, Greer B, McCarthy HO, Paredes AJ, Larrañeta E, Donnelly RF. Transdermal Delivery of Pramipexole Using Microneedle Technology for the Potential Treatment of Parkinson's Disease. Mol Pharm 2024; 21:2512-2533. [PMID: 38602861 PMCID: PMC11080471 DOI: 10.1021/acs.molpharmaceut.4c00065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Revised: 03/25/2024] [Accepted: 03/26/2024] [Indexed: 04/13/2024]
Abstract
Parkinson's disease (PD) is a debilitating neurodegenerative disease primarily impacting neurons responsible for dopamine production within the brain. Pramipexole (PRA) is a dopamine agonist that is currently available in tablet form. However, individuals with PD commonly encounter difficulties with swallowing and gastrointestinal motility, making oral formulations less preferable. Microneedle (MN) patches represent innovative transdermal drug delivery devices capable of enhancing skin permeability through the creation of microconduits on the surface of the skin. MNs effectively reduce the barrier function of skin and facilitate the permeation of drugs. The work described here focuses on the development of polymeric MN systems designed to enhance the transdermal delivery of PRA. PRA was formulated into both dissolving MNs (DMNs) and directly compressed tablets (DCTs) to be used in conjunction with hydrogel-forming MNs (HFMNs). In vivo investigations using a Sprague-Dawley rat model examined, for the first time, if it was beneficial to prolong the application of DMNs and HFMNs beyond 24 h. Half of the patches in the MN cohorts were left in place for 24 h, whereas the other half remained in place for 5 days. Throughout the entire 5 day study, PRA plasma levels were monitored for all cohorts. This study confirmed the successful delivery of PRA from DMNs (Cmax = 511.00 ± 277.24 ng/mL, Tmax = 4 h) and HFMNs (Cmax = 328.30 ± 98.04 ng/mL, Tmax = 24 h). Notably, both types of MNs achieved sustained PRA plasma levels over a 5 day period. In contrast, following oral administration, PRA remained detectable in plasma for only 48 h, achieving a Cmax of 159.32 ± 113.43 ng/mL at 2 h. The HFMN that remained in place for 5 days demonstrated the most promising performance among all investigated formulations. Although in the early stages of development, the findings reported here offer a hopeful alternative to orally administered PRA. The sustained plasma profile observed here has the potential to reduce the frequency of PRA administration, potentially enhancing patient compliance and ultimately improving their quality of life. This work provides substantial evidence advocating the development of polymeric MN-mediated drug delivery systems to include sustained plasma levels of hydrophilic pharmaceuticals.
Collapse
Affiliation(s)
- Mary B. McGuckin
- School
of Pharmacy, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom
| | - Aaron R.J. Hutton
- School
of Pharmacy, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom
| | - Ellie R. Davis
- School
of Pharmacy, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom
| | - Akmal H.B. Sabri
- School
of Pharmacy, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom
| | - Anastasia Ripolin
- School
of Pharmacy, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom
| | - Achmad Himawan
- School
of Pharmacy, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom
| | - Yara A. Naser
- School
of Pharmacy, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom
| | - Rand Ghanma
- School
of Pharmacy, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom
| | - Brett Greer
- Institute
for Global Food Security, School of Biological Sciences, Queen’s University Belfast, 19 Chlorine Gardens, Belfast BT9 5DL, United Kingdom
- The International
Joint Research Centre on Food Security (IJC-FOODSEC), 113 Thailand Science Park, Pahonyothin
Road, Khong Luang ,Pathum
Thani12120, Thailand
| | - Helen O. McCarthy
- School
of Pharmacy, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom
| | - Alejandro J. Paredes
- School
of Pharmacy, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom
| | - Eneko Larrañeta
- School
of Pharmacy, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom
| | - Ryan F. Donnelly
- School
of Pharmacy, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom
| |
Collapse
|
2
|
Amirighadi S, Raoof JB, Chekin F, Ojani R. A sensitive voltammetric detection of pramipexole based on 1,1,3,3-tetramethyldisilazanecarbon nanotube modified electrode. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2017; 75:784-790. [DOI: 10.1016/j.msec.2017.02.072] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/30/2016] [Revised: 10/23/2016] [Accepted: 02/14/2017] [Indexed: 11/26/2022]
|
3
|
Development and validation of a highly sensitive gradient chiral separation of pramipexole in human plasma by LC–MS/MS. Bioanalysis 2017; 9:683-692. [DOI: 10.4155/bio-2016-0265] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Aim: Development of a high-sensitivity chiral LC–MS/MS method was required to evaluate a combination of pramipexole (S-PPX) and its enantiomer dexpramipexole (R-PPX) in a proposed clinical trial. The previously available methods suffered from low sensitivity for the (S)-enantiomer in the presence of the more abundant (R)-enantiomer. Based on the projected dosing regimen in the clinical trial, a 5000-fold improvement in sensitivity was required for the (S)-enantiomer. Methodology: Spiked human plasma samples were extracted by liquid–liquid extraction using ethyl acetate and injected onto a CHIRALPAK ID column under pH gradient conditions. Conclusion: An improved analytical method was developed and validated with a final LLQ for (S)-PPX of 0.1 ng/ml in the presence of 2000 ng/ml of (R)-PPX.
Collapse
|
4
|
Parsha S, Kumar YR, Ravichander M. LC–MS/MS and NMR Characterization of Key Impurities in Linagliptin and Pramipexole. J LIQ CHROMATOGR R T 2015. [DOI: 10.1080/10826076.2015.1087861] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Swetha Parsha
- Department of Analytical Research and Development, Integrated Product Development, Dr. Reddy’s Laboratories, Hyderabad, India
- Department of Chemistry, Jawaharlal Nehru Technological University, Hyderabad, India
| | - Y. Ravindra Kumar
- Department of Analytical Research and Development, Integrated Product Development, Dr. Reddy’s Laboratories, Hyderabad, India
| | - M. Ravichander
- Department of Chemistry, Mahatma Gandhi Institute of Technology, Hyderabad, India
| |
Collapse
|
5
|
Ramisetti NR, Kuntamukkala R, Arnipalli MS. Development of a Validated LC Method for Separation of Process-Related Impurities Including the R-Enantiomer of S-Pramipexole on Polysaccharide Chiral Stationary Phases. Chirality 2015; 27:430-5. [PMID: 25966024 DOI: 10.1002/chir.22461] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2014] [Revised: 03/19/2015] [Accepted: 04/10/2015] [Indexed: 11/08/2022]
Abstract
Despite the availability of a few methods for individual separation of S-pramipexole from its process-related impurities, no common liquid chromatography (LC) method is reported so far in the literature. The present article describes the development of a single-run LC method for simultaneous determination of S-pramipexole and its enantiomeric and process-related impurities on a Chiralpak AD-H (150 x 4.6 mm, 5μm) column using n-hexane/ethanol/n-butylamine (75:25:0.1 v/v/v) as a mobile phase in an isocratic mode of elution at a flow rate of 1.2 ml/min at 30°C. The chromatographic eluents were monitored at a wavelength of 260 nm using a photodiode array detector. Excellent enantioseparation with good resolutions (Rs ≥ 2.88) and peak shapes (As ≤ 1.21) for all analytes was achieved. The proposed method was validated according to International Conference Harmonization (ICH) guidelines in terms of accuracy, precision, sensitivity, and linearity. Limits of quantification of impurities (0.25-0.55 μg/ml) indicate the highest sensitivity achievable by the proposed method. The method has an advantage of selectivity and suitability for routine determination of not only chiral impurity but also all possible related substances in active pharmaceutical ingredients of S-pramipexole.
Collapse
Affiliation(s)
- Nageswara Rao Ramisetti
- D215, Discovery Lab, Analytical Chemistry Division, Indian Institute of Chemical Technology, Tarnaka, Hyderabad, India
| | - Ramakrishna Kuntamukkala
- D215, Discovery Lab, Analytical Chemistry Division, Indian Institute of Chemical Technology, Tarnaka, Hyderabad, India
| | - Manikanta Swamy Arnipalli
- D215, Discovery Lab, Analytical Chemistry Division, Indian Institute of Chemical Technology, Tarnaka, Hyderabad, India
| |
Collapse
|
6
|
Guo W, Li G, Yang Y, Yang C, Si L, Huang J. LC-MS/MS analysis of pramipexole in mouse plasma and tissues: Elimination of lipid matrix effects using weak cation exchange mode based solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2015; 988:157-65. [DOI: 10.1016/j.jchromb.2015.02.032] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Revised: 02/15/2015] [Accepted: 02/25/2015] [Indexed: 01/04/2023]
|
7
|
Wei D, Wu C, He P, Kerr D, Stecher S, Yang L. Chiral liquid chromatography–tandem mass spectrometry assay to determine that dexpramipexole is not converted to pramipexole in vivo after administered in humans. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 971:133-40. [DOI: 10.1016/j.jchromb.2014.09.029] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2014] [Revised: 09/04/2014] [Accepted: 09/21/2014] [Indexed: 10/24/2022]
|
8
|
Ghasemi E, Kheradmand S, Ghorban Dadrass O. Solvent bar microextraction combined with high-performance liquid chromatography for preconcentration and determination of pramipexole in biological samples. Biomed Chromatogr 2013; 28:486-91. [DOI: 10.1002/bmc.3058] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2013] [Revised: 08/15/2013] [Accepted: 09/05/2013] [Indexed: 11/09/2022]
Affiliation(s)
- Ensieh Ghasemi
- Department of Chemistry, Pharmaceutical Sciences Branch; Islamic Azad University; Tehran Iran
| | - Salim Kheradmand
- Department of Chemistry, Pharmaceutical Sciences Branch; Islamic Azad University; Tehran Iran
| | - Orkideh Ghorban Dadrass
- Department of Medicinal Chemistry, Pharmaceutical Sciences Branch; Islamic Azad University; Tehran Iran
| |
Collapse
|
9
|
LC-MS/MS determination of pramipexole on rat dried blood spots: a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 932:34-9. [PMID: 23831524 DOI: 10.1016/j.jchromb.2013.06.012] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2013] [Revised: 05/28/2013] [Accepted: 06/09/2013] [Indexed: 12/31/2022]
Abstract
A simple and selective liquid chromatography-tandem mass spectrometric method for determination of pramipexole on rat dried blood spots was developed and validated. Chromatographic separation was achieved on a Synergy polar-RP column using 10mM ammonium acetate and methanol (50:50, v/v) as mobile phase in an isocratic mode of elution at a flow rate of 1.0mL/min. LC-MS was performed in a positive ion electro spray ionization mode and the MS/MS ion transitions 212.10→153.03 for PRX and 198.10→153.03 for internal standard (2-amino-4,5,6,7-tetrahydro-6-ethyl-amino-benzthiazole) were monitored. The developed method exhibited a linear dynamic range over 100-5000pg/mL for PRX on dried blood spots. The overall extraction recovery of PRX from DBS was 96.7%. The intra- and inter-day accuracy and precision were within the pre-defined limits of ≤15% at all concentrations. Influence of hematocrit and spot volume on dried blood spot was also evaluated and found to be well within the acceptable limits. The method was successfully applied to pharmacokinetic studies of PRX in rats.
Collapse
|
10
|
Pawar SM, Khatal LD, Gabhe SY, Dhaneshwar SR. Establishment of inherent stability of pramipexole and development of validated stability indicating LC-UV and LC-MS method. J Pharm Anal 2012; 3:109-117. [PMID: 29403804 PMCID: PMC5760940 DOI: 10.1016/j.jpha.2012.07.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2012] [Accepted: 07/19/2012] [Indexed: 11/24/2022] Open
Abstract
Pramipexole belongs to a class of nonergot dopamine agonist recently approved for the treatment of early and advanced Parkinson's disease. A validated specific stability indicating reversed-phase liquid chromatographic method has been developed for the quantitative determination of pramipexole in bulk as well as in pharmaceutical dosage forms in the presence of degradation products. Forced degradation studies were performed by exposition of drug to hydrolytic (acidic and basic), oxidative and photolytic stress conditions, as defined under ICH guideline Q1A (R2). Significant degradation was observed under hydrolytic, oxidative and photolytic conditions and the degradation products formed were identified by LC–MS.
Collapse
Affiliation(s)
- Shubhangi M Pawar
- Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth University, Pune, Maharashtra 411038, India
| | - Laxman D Khatal
- Bioanalytical Research Department, BioAnalytical Technologies Pvt. Ltd., Pune, Maharashtra 411030, India
| | - Satish Y Gabhe
- Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth University, Pune, Maharashtra 411038, India
| | - Sunil R Dhaneshwar
- Department of Pharmaceutical Chemistry, RAK Medical and Health Sciences University, College of Pharmaceutical Sciences, Ras Al Khaimah 11172, United Arab Emirates
| |
Collapse
|
11
|
Development of a rapid and sensitive SPE-LC-MS/MS method for the simultaneous estimation of fluoxetine and olanzapine in human plasma. Biomed Chromatogr 2011; 26:1077-82. [DOI: 10.1002/bmc.1750] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2011] [Revised: 10/08/2011] [Accepted: 10/08/2011] [Indexed: 11/07/2022]
|
12
|
Pawar SM, Dhaneshwar SR. APPLICATION OF STABILITY INDICATING HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHIC METHOD FOR QUANTITATION OF PRAMIPEXOLE IN PHARMACEUTICAL DOSAGE FORM. J LIQ CHROMATOGR R T 2011. [DOI: 10.1080/10826076.2011.576301] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- Shubhangi M. Pawar
- a Department of Pharmaceutical Chemistry , Bharati Vidyapeeth University, Poona College of Pharmacy , Pune, Maharashtra, India
| | - Sunil R. Dhaneshwar
- a Department of Pharmaceutical Chemistry , Bharati Vidyapeeth University, Poona College of Pharmacy , Pune, Maharashtra, India
| |
Collapse
|
13
|
Deng X, Hai X, Vervoort R, Pamperin D, Adams E, Van Schepdael A. Development and validation of a chiral capillary electrophoresis method for assay and enantiomeric purity control of pramipexole. J Sep Sci 2011; 34:3070-6. [DOI: 10.1002/jssc.201100444] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2011] [Revised: 07/22/2011] [Accepted: 07/22/2011] [Indexed: 11/06/2022]
|
14
|
Panchal JG, Patel RV, Menon SK. Development and validation of GC/MS method for determination of pramipexole in rat plasma. Biomed Chromatogr 2011; 25:524-30. [DOI: 10.1002/bmc.1478] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
15
|
Jenner P, Könen-Bergmann M, Schepers C, Haertter S. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther 2010; 31:2698-711. [PMID: 20110012 DOI: 10.1016/j.clinthera.2009.10.018] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/20/2009] [Indexed: 02/07/2023]
Abstract
BACKGROUND Pramipexole is a dopamine agonist used in the treatment of Parkinson's disease. The currently available immediate-release (IR) formulation is taken orally 3 times daily. OBJECTIVES These studies were conducted to evaluate the pharmacokinetic properties of a variety of prototypes for a once-daily extended-release (ER) formulation of pramipexole and to further characterize the prototype whose pharmacokinetics best matched those of the IR formulation. METHODS Three Phase I studies were conducted, all in healthy adult men aged <or=50 years with a body mass index of 18.5 to 29.9 kg/m(2). In the first study, 7 prototypes of a once-daily ER formulation with various release properties, including rate and pH dependence, were compared with the IR formulation taken 3 times daily to identify the optimal pharmacokinetic resemblance based on predefined criteria derived from plasma AUC(0-24h), C(max), and C(min). In the second study, a level A in vitro/in vivo correlation (IVIVC) suitable for predicting an entire in vivo bioavailability time course based on in vitro dissolution was established and validated, and the single-dose pharmacokinetics of the optimal ER formulation identified in the first study were analyzed for food effect. In the third study, steady-state pharmacokinetics of the optimal ER formulation were assessed across a range of pramipexole doses (0.375-4.5 mg/d), including investigation of the food effect at steady state for the highest dose. Tolerability was assessed throughout all studies based on physical examinations, laboratory measurements, and adverse events (AEs). RESULTS The 3 studies included 18, 15, and 39 subjects, respectively. Among the ER prototypes tested at 0.75 mg once daily in study 1, a matrix tablet had the optimal pharmacokinetic resemblance to IR pramipexole 0.25 mg TID, with a geometric mean AUC(0-24h,ss) of 17.4 ng.h/mL (vs 16.0 ng.h/mL for the IR formulation), C(max,ss) of 0.967 ng/mL (vs 1.09 ng/mL), and C(min,ss) of 0.455 ng/mL (vs 0.383 ng/mL). For single-dose ER 0.375 mg administered in the fasted state in study 2, in vivo bioavailability was predictable from in vitro dissolution data, with internal mean absolute percent prediction errors of 3.18% for AUC(0-30h) and 4.87% for C(max), and external mean absolute prediction errors of 6.61% and 3.34%, respectively, satisfying current guidelines for a level A IVIVC. For single-dose ER 0.375 mg administered in the fed state, the upper bound of the 90% CI for fed:fasted values was 119.8 for AUC(0-30h) (within the bioequivalence limits of 80%-125%) and 134.1 for C(max). At steady state in study 3 (subjects' 5th treatment day), dosing at 0.375 to 4.5 mg in the fasted state was associated with a linear, dose-proportional increase in pharmacokinetic parameters, including AUC(0-24h,ss) and C(max,ss). At the highest fasted dose (4.5 mg), the geometric coefficient of variation for interindividual variability at steady state was 30.1% for AUC(0-24h,ss) (vs 21.4% for IR pramipexole 1.5 mg TID) and 22.3% for C(max,ss) (vs 19.0%). At steady state, the upper bounds of the 90% CIs for fed:fasted values with ER 4.5 mg were 122.1 for AUC(0-24h) and 126.8 for C(max). No serious AEs occurred, and the dropout rate was low. CONCLUSIONS In these studies in healthy male volunteers, an ER pramipexole formulation was identified that resembled the IR formulation in terms of both pharmacokinetics and tolerability. In patients with Parkinson's disease, once-daily use of an ER formulation may improve the convenience of treatment relative to the IR formulation taken 3 times daily and thus increase compliance.
Collapse
Affiliation(s)
- Peter Jenner
- Neurodegenerative Disease Research Centre, School of Biomedical and Health Sciences, King's College London, London, United Kingdom
| | | | | | | |
Collapse
|
16
|
Bharathi DV, Hotha KK, Sagar PVV, Kumar SS, Naidu A, Mullangi R. Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of pramipexole in human plasma: application to a clinical pharmacokinetic study. Biomed Chromatogr 2009; 23:212-8. [DOI: 10.1002/bmc.1108] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
17
|
Musenga A, Kenndler E, Morganti E, Rasi F, Raggi MA. Analysis of the anti-Parkinson drug pramipexole in human urine by capillary electrophoresis with laser-induced fluorescence detection. Anal Chim Acta 2008; 626:89-96. [DOI: 10.1016/j.aca.2008.07.035] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2008] [Revised: 07/18/2008] [Accepted: 07/21/2008] [Indexed: 10/21/2022]
|
18
|
Villalba MM, Davis J. New directions for carbon-based detectors: exploiting the versatility of carbon substrates in electroanalysis. J Solid State Electrochem 2008. [DOI: 10.1007/s10008-008-0535-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Lv YF, Hu X, Bi KS. Determination of mildronate in human plasma and urine by liquid chromatography–tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 852:35-9. [PMID: 17287154 DOI: 10.1016/j.jchromb.2006.12.031] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2006] [Revised: 12/14/2006] [Accepted: 12/28/2006] [Indexed: 11/23/2022]
Abstract
A sensitive and selective analytical method based on liquid chromatography-triple-quadrupole mass spectrometer has been developed to determine mildronate in human plasma and urine. The aim of this work was to find a valid method to study the pharmacokinetic profiles of mildronate in humans. Mildronate is a heart protection medicine, a carnitine's structural analogue, so levocarnitine was used as an internal standard for quantification. Under the electrospray ionization source positive ion mode, calibration curves with good linearities (r=0.9998 for plasma sample and r=0.9999 for urine sample) were obtained in the range of 1.0-20,000 ng ml(-1) for mildronate. The detection limit was 1 ng ml(-1). Recoveries were around 90% for the extraction from human plasma, and good precision and accuracy were achieved. This method is feasible for the evaluation of pharmacokinetic profiles of mildronate in humans, and to the best of our knowledge, this is the first report on LC-MS-MS analysis of mildronate in plasma and urine.
Collapse
Affiliation(s)
- Yun-Feng Lv
- School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, Liaoning Province, PR China
| | | | | |
Collapse
|
20
|
Jančić B, Medenica M, Ivanović D, Malenović A. Chromatographic Determination of Dissociation Constants of Pramipexole and its Impurities. Chromatographia 2007. [DOI: 10.1365/s10337-007-0199-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
21
|
Nirogi RVS, Kandikere V, Shrivastava W, Mudigonda K, Maurya S, Ajjala D. Quantification of pramipexole in human plasma by liquid chromatography tandem mass spectrometry using tamsulosin as internal standard. Biomed Chromatogr 2007; 21:1151-8. [PMID: 17583880 DOI: 10.1002/bmc.864] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
A high-performance liquid chromatography/electrospray ionization tandem mass spectrometry method was developed and validated for the quantification of pramipexole in human plasma. Following liquid-liquid extraction, the analytes were separated using an isocratic mobile phase on a reverse-phase column and analyzed by MS/MS in the multiple reaction monitoring mode using the respective [M + H](+) ions, m/z 212/152 for pramipexole and m/z 409/228 for the IS. The method exhibited a linear dynamic range of 200-8000 pg/mL for pramipexole in human plasma. The lower limit of quantification was 200 pg/mL with a relative standard deviation of less than 8%. Acceptable precision and accuracy were obtained for concentrations over the standard curve range. A run time of 3.5 min for each sample made it possible to analyze more than 200 human plasma samples per day. The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies.
Collapse
Affiliation(s)
- Ramakrishna V S Nirogi
- Biopharmaceutical Research, Suven Life Sciences Ltd, Serene Chambers, Road No. 5, Avenue 7, Banjara Hills, Hyderabad, India.
| | | | | | | | | | | |
Collapse
|
22
|
Srinubabu G, Jaganbabu K, Sudharani B, Venugopal K, Girizasankar G, Rao JVLNS. Development and Validation of a LC Method for the Determination of Pramipexole Using an Experimental Design. Chromatographia 2006. [DOI: 10.1365/s10337-006-0829-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
23
|
Pathare DB, Jadhav AS, Shingare MS. Validated chiral liquid chromatographic method for the enantiomeric separation of Pramipexole dihydrochloride monohydrate. J Pharm Biomed Anal 2006; 41:1152-6. [PMID: 16580170 DOI: 10.1016/j.jpba.2006.02.024] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2006] [Revised: 02/13/2006] [Accepted: 02/14/2006] [Indexed: 11/29/2022]
Abstract
A chiral liquid chromatographic method was developed for the enantiomeric resolution of Pramipexole dihydrochloride monohydrate, (S)-2-amino-4,5,6,7-tetra-hydro-6-(propylamino) benzothiazole dihydrochloride monohydrate, a dopamine agonist in bulk drugs. The enantiomers of Pramipexole dihydrochloride monohydrate were resolved on a Chiralpak AD (250 mm x 4.6 mm, 10 microm) column using a mobile phase system containing n-hexane:ethanol:diethylamine (70:30:0.1, v/v/v). The resolution between the enantiomers was found not less than eight. The presence of diethylamine in the mobile phase has played an important role in enhancing chromatographic efficiency and resolution between the enantiomers. The developed method was extensively validated and proved to be robust. The limit of detection and limit of quantification of (R)-enantiomer were found to be 300 and 900 ng/ml, respectively for 20 microl injection volume. The percentage recovery of (R)-enantiomer was ranged from 97.3 to 102.0 in bulk drug samples of Pramipexole dihydrochloride monohydrate. Pramipexole dihydrochloride monohydrate sample solution and mobile phase were found to be stable for at least 48 h. The proposed method was found to be suitable and accurate for the quantitative determination of (R)-enantiomer in bulk drugs.
Collapse
Affiliation(s)
- D B Pathare
- Department of Chemistry, Dr. B.A. Marathawada University, Aurangabad 431 004, India
| | | | | |
Collapse
|
24
|
Zhang JY, Fast DM, Breau AP. Development and validation of an automated SPE-LC-MS/MS assay for valdecoxib and its hydroxylated metabolite in human plasma. J Pharm Biomed Anal 2003; 33:61-72. [PMID: 12946532 DOI: 10.1016/s0731-7085(03)00349-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
A sensitive and specific liquid chromatography-tandem mass spectrometry assay was developed to quantitate valdecoxib (I) and its hydroxylated metabolite (II) in human plasma. The analytes (I and II) and a structurally analogue internal standard (IS) were extracted on a C(18) solid phase extraction (SPE) cartridge using a Zymark RapidTrace automation system. The chromatographic separation was performed on a narrow-bore reverse phase Zorbax XDB-C(8) HPLC column with a mobile phase of acetonitrile:water (50:50, v/v) containing 10 mM ammonium acetate. The analytes were ionized using negative electrospray mass spectrometry, then detected by multiple reaction monitoring (MRM) with a tandem mass spectrometer. The precursor to product ion transitions of m/z 313-->118 and m/z 329-->196 were used to measure I and II, respectively. The assay exhibited a linear dynamic range of 0.5-200 ng/ml of I and II in human plasma with absolute recoveries from plasma at 91 and 86%, respectively. The lower limit of quantitation was 0.5 ng/ml for I and II. Acceptable precision and accuracy were obtained for concentrations over the calibration curve ranges (0.5-200 ng/ml). Sample analysis time for each injection was 5 min, a throughput of 70 human plasma standards and samples per run was achieved. The assay has been successfully used to analyze human plasma samples to support clinical phase I and II studies.
Collapse
Affiliation(s)
- Ji Y Zhang
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., 4901 Searle Parkway, Skokie, IL 60077, USA.
| | | | | |
Collapse
|
25
|
Kamel A, Prakash C, Saverino C, Obach B, Fouda H. Narrow-bore high-performance liquid chromatography in combination with ionspray tandem mass spectrometry for the determination of the substance P receptor antagonist ezlopitant and its two active metabolites in plasma. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 2000; 748:179-88. [PMID: 11092597 DOI: 10.1016/s0378-4347(00)00361-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
A simple, but highly sensitive and specific, assay was developed for the quantitative determination of ezlopitant and its two active metabolites in human plasma using narrow-bore reversed-phase high-performance liquid chromatography (HPLC) coupled with electrospray tandem mass spectrometry (ES-MS-MS). Ezlopitant, its two pharmacologically active metabolites, an alkene analogue (CJ-12 458) and a benzyl alcohol analogue (CJ-12 764), and their corresponding trideuterated internal standards (I.S.), were extracted from plasma with methyl tert.-butyl ether (MTBE). The dried MTBE extracts were reconstituted and analyzed using a narrow-bore (2.1 mm I.D.) YMC basic HPLC column and a mobile phase of acetonitrile-20 mM ammonium acetate, pH 5 (60:40, v/v). Column effluent was monitored by pneumatically assisted electrospray tandem mass spectrometry. Multiple reaction monitoring (MRM) using the parent to product ions was used to quantify ezlopitant and its two active metabolites. The assay exhibited a linear dynamic range of 0.1-100 ng/ml. Average absolute recoveries from plasma were approximately 71, 80 and 99% for ezlopitant and its two active metabolites CJ-12 485 and CJ-12 764, respectively. The precision (RSD %) and accuracy (Deviation %) values for the method were within +/- 12% and +/- 15%, respectively, for all analytes. Sample analysis times were less than 5 min from one injection to the next. The assay proved to be suitable for pharmacokinetics studies.
Collapse
Affiliation(s)
- A Kamel
- Department of Drug Metabolism, Global Research and Development, Pfizer Inc, Groton, CT 06340, USA
| | | | | | | | | |
Collapse
|
26
|
Maurer HH. Liquid chromatography-mass spectrometry in forensic and clinical toxicology. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 1998; 713:3-25. [PMID: 9700550 DOI: 10.1016/s0378-4347(97)00514-8] [Citation(s) in RCA: 160] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
This paper reviews liquid chromatographic-mass spectrometric (LC-MS) procedures for the identification and/or quantification of drugs of abuse, therapeutic drugs, poisons and/or their metabolites in biosamples (whole blood, plasma, serum, urine, cerebrospinal fluid, vitreous humor, liver or hair) of humans or animals (cattle, dog, horse, mouse, pig or rat). Papers published from 1995 to early 1997, which are relevant to clinical toxicology, forensic toxicology, doping control or drug metabolism and pharmacokinetics, were taken into consideration. They cover the following analytes: amphetamines, cocaine, lysergide (LSD), opiates, anabolics, antihypertensives, benzodiazepines, cardiac glycosides, corticosteroids, immunosuppressants, neuroleptics, non-steroidal anti-inflammatory drugs (NSAID), opioids, quaternary amines, xanthins, biogenic poisons such as aconitines, aflatoxins, amanitins and nicotine, and pesticides. LC-MS interface types, mass spectral detection modes, sample preparation procedures and chromatographic systems applied in the reviewed papers are discussed. Basic information about the biosample assayed, work-up, LC column, mobile phase, interface type, mass spectral detection mode, and validation data of each procedure is summarized in tables. Examples of typical LC-MS applications are presented.
Collapse
Affiliation(s)
- H H Maurer
- Department of Toxicology, University of Saarland, Homburg (Saar), Germany
| |
Collapse
|
27
|
Kamel A, Prakash C. Determination of the substance P receptor antagonist CP-122,721 in plasma by narrow-bore high-performance liquid chromatography-ionspray tandem mass spectrometry. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 1997; 700:139-46. [PMID: 9390723 DOI: 10.1016/s0378-4347(97)00315-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
A simple, highly sensitive and specific LC-MS-MS assay was developed for the determination of CP-122,721 (I) in rat and human plasma. I and a structural analog, CP-129,943 (II, internal standard), were extracted from plasma with methyl tert.-butyl ether (MTBE). The dried MTBE extracts were reconstituted and analyzed using a narrow-bore (2.1 mm I.D.) YMC basic HPLC column and a mobile phase of acetonitrile-20 mM ammonium acetate, pH 5 (50:50, v/v). Column effluents were monitored by ionspray tandem mass spectrometry. Multiple reaction monitoring (MRM) using the parent to product ion combinations of m/z 381-->205 and 395-->219 was used to quantitate I and II, respectively. The assay exhibited a linear dynamic range of 0.2-100 ng/ml. Absolute recoveries from plasma were above 80% for both I and II. The precision and accuracy values for the method were within +/-3 and +/-9%, respectively. Sample analysis times were less than 5 min from one injection to the next. The assay has proved to be applicable to the pharmacokinetic study of I in rats.
Collapse
Affiliation(s)
- A Kamel
- Department of Drug Metabolism, Pfizer Inc., Groton, CT 06340, USA
| | | |
Collapse
|